Recent articles
Better Buy: Eli Lilly vs. Pfizer
Both of these pharma giants are working on a coronavirus vaccine, but there's more to the story.
Why Immunic Stock Is Soaring Today
An analyst says buy.
Is Gilead Sciences a Buy After Its Most Recent Roadblock?
One of the biotech's most promising candidates failed to earn FDA approval. Should investors jump ship?
Why Orchard Therapeutics Stock Is Soaring Today
No news is good news for this biotech company.
Why Is Everyone Talking About Pfizer?
Its coronavirus vaccine effort is grabbing headlines, but this company isn't a one-trick pony.
Don’t Buy Aurora Cannabis Stock Until These 2 Things Happen
Here's how this pot producer could get back on the right track.
Is Aphria Stock a Buy?
Is this cannabis company's post-earnings sell-off a buying opportunity?
My Top Pharma Stock to Buy in the Next Market Crash
The future is bright for this drugmaker and its shareholders. Just wait for the dip.
This Expensive Growth Stock Hasn’t Peaked Yet
The virtual patient care boom brought on by the pandemic is pushing this company higher.
Why BioXcel Therapeutics Stock Is Down Today
Investors were not impressed with the company's latest quarterly update.
2 Forever Pharma Stocks to Buy Now
Only one of these stocks has performed well this year, but both are worth buying and holding over the long term.
Why Inovio Pharmaceuticals Stock Is Up Today
After a rough week on the stock market for the biotech company, investors finally think the price is right.
2 Large-Cap Stocks You Can Buy Right Now
These two companies will get you through the coronavirus crisis -- and beyond.
Is Inovio Pharmaceuticals Stock a Buy?
Could this biotech stock be a major winner down the road?
2 Revolutionary Biotech Stocks to Buy Right Now
Each of these companies has the potential to generate life-changing returns.
Why Trevena Stock Is Plunging Today
The biopharmaceutical company announced the pricing of a public offering of common stock.
Why Tilray Stock Is Plunging Today
The company released its second-quarter financial results.
Could This Small-Cap Biotech Stock Make You Rich?
Thanks to bad news for its competitor, this company behind the first FDA-approved peanut allergy treatment could be ripe for a rebound.
Why Axsome Therapeutics Stock Rose Today
The company announced that it is on track to submit two of its pipeline candidates to the FDA by year-end.
Why Reata Pharmaceuticals Stock Is Plunging Today
The clinical-stage drug company may not be able to file for FDA approval of a top candidate as soon as expected.